Glucagon-like peptide-1 receptor agonists and their effects on weight reduction
نویسندگان
چکیده
منابع مشابه
Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
Overweight and obesity seriously damages human health. The World Health Organization estimates that 1.5 billion adults were overweight in the year of 2011. Of this overweight population, over 200 million men and nearly 300 million women were obese. At least 2.8 million adults die each year as a result of being overweight or obese. A total of 44% of the diabetes burden and 23% of the ischemic he...
متن کاملEffects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs), approved as glucose-lowering drugs for the treatment of type 2 diabetes, have also been shown to reduce body weight. An extensive Medline, Cochrane database, and Embase search for "exenatide," "liraglutide," "albiglutide," "semaglutide," and "lixisenatide" was performed, collecting all randomized clinical trials on humans up to December 15, ...
متن کاملCardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade. The benefits of GLP-1 RAs are derived from their pleiotropic effects, which include glucose-dependent insulin secretion, suppressed glucagon secretion, and reduced appetite. Moreover, GLP-1 RAs also ...
متن کاملAn overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be...
متن کاملSmall-molecule agonists for the glucagon-like peptide 1 receptor.
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes. As a peptide hormone, GLP-1 has to be administered by injection. Only a few small-molecule agonists to peptide hormone receptors have been described and none in the B family of the G protein coupled receptors to which the GLP-1 receptor b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes Investigation
سال: 2012
ISSN: 2040-1116
DOI: 10.1111/j.2040-1124.2012.00241.x